Pharmacists must be aware of potentially serious adverse reactions in patients receiving angiotensin- converting enzyme therapy, particularly with the concurrent use of dipeptidly peptidase IV inhibitors.
Shahnawaz Khan, RPh
Advertisement
Articles by Shahnawaz Khan, RPh
Advertisement
Latest Updated Articles
- Treatment of Diabetes and Angioedema Risk
Published: October 10th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Estradiol-Containing MHT May Impact Alzheimer Disease-Related Biomarkers in Postmenopausal Women
2
CHEST 2025: Exploring the Link Between GLP-1 Receptor Agonists, Type 2 Diabetes, and Asthma Risk
3
CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution
4
MHT Use Can Affect Cognitive Health Depending on Administration Method
5
